Modus Therapeutics Holding AB (ST:MODTX) — Market Cap & Net Worth
Market Cap & Net Worth: Modus Therapeutics Holding AB (MODTX)
Modus Therapeutics Holding AB (ST:MODTX) has a market capitalization of $7.57 Million (Skr70.31 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27822 globally and #607 in its home market, demonstrating a -8.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Modus Therapeutics Holding AB's stock price Skr0.40 by its total outstanding shares 175775089 (175.78 Million). Also see total assets of Modus Therapeutics Holding AB for a full breakdown of the balance sheet.
Modus Therapeutics Holding AB Market Cap History: 2021 to 2026
Modus Therapeutics Holding AB's market capitalization history from 2021 to 2026. Data shows change from $71.88 Million to $7.57 Million (-39.27% CAGR). Also see Modus Therapeutics Holding AB cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Modus Therapeutics Holding AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.23 Billion | 0.05% | #172 of 281 |
Weight: Modus Therapeutics Holding AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Modus Therapeutics Holding AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Modus Therapeutics Holding AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MODTX share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MODTX by Market Capitalization
Companies near Modus Therapeutics Holding AB in the global market cap rankings as of September 19, 2026. Review Modus Therapeutics Holding AB tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Modus Therapeutics Holding AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Modus Therapeutics Holding AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Modus Therapeutics Holding AB's market cap moved from $71.88 Million to $ 7.57 Million, with a yearly change of -39.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr7.57 Million | +31.58% |
| 2025 | Skr5.75 Million | -83.16% |
| 2024 | Skr34.14 Million | +4.03% |
| 2023 | Skr32.82 Million | -37.81% |
| 2022 | Skr52.78 Million | -26.58% |
| 2021 | Skr71.88 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Modus Therapeutics Holding AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.57 Million USD |
| MoneyControl | $7.57 Million USD |
| MarketWatch | $7.57 Million USD |
| marketcap.company | $7.57 Million USD |
| Reuters | $7.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more